April 28, 2006


Act 128-1992 amending the Lottery Fund Preservation Act, in part, requires all pharmaceutical manufacturers to have in effect a rebate agreement with the PACE Program if they wish to have their products covered.  In effecting the rebate provisions of Act 134-1996, PACE, the Chronic Renal Disease Program (CRDP) and the Special Pharmaceutical Benefits Program (SPBP) will preclude payment for all products marketed by those manufacturers who either have not signed a PACE rebate agreement or have not complied with the agreement provisions.


Please note the following manufacturer is being added to PACE’s non-participating list:


          NABI (North American Biological Inc) Labeler Code – 59730


NOTE: NABI has the exclusive rights to Phoslo®. 


All products of NABI, including Phoslo®, are no longer reimbursable effective May 29, 2006.


Questions regarding this bulletin should be directed to:

Nabi Biopharmaceuticals

Corporate Headquarters and Manufacturing Facility

5800 Park of Commerce Blvd., N.W.

Boca Raton, Florida